@article{f92f8624d72d45b384c4327bc627983e,
title = "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia",
keywords = "Adult, Advisory Committees, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal/therapeutic use, Anticholesteremic Agents/therapeutic use, Coronary Artery Disease/drug therapy, Female, Humans, Hyperlipoproteinemia Type II/drug therapy, Male, Middle Aged, Proprotein Convertase 9/antagonists & inhibitors",
author = "Ulf Landmesser and Chapman, {M. John} and Stock, {Jane K} and Pierre Amarenco and Belch, {Jill J F} and Jan Bor{\'e}n and Michel Farnier and Ference, {Brian A} and Stephan Gielen and Ian Graham and Grobbee, {Diederick E} and Hovingh, {G. Kees} and L{\"u}scher, {Thomas Felix} and Piepoli, {Massimo F.} and Ray, {Kausik K.} and Stroes, {Erik S G} and Olov Wiklund and Stephan Windecker and Zamorano, {Jose Luis} and Fausto Pinto and Lale Tokg{\"o}zoglu and Bax, {Jeroen J.} and Catapano, {Alberico L.}",
note = "Funding Information: Funding for travel to participate in Task Force meetings was provided by the European Atherosclerosis Society.",
year = "2018",
month = apr,
day = "7",
doi = "10.1093/eurheartj/ehx549",
language = "English",
volume = "39",
pages = "1131--1143",
number = "14",
}